Xinnate

22 October 2026

EB awareness

During EB Awareness Week 2026, October 25–31, Xinnate campaigns in collaboration with the global patient organization DEBRA International to raise awareness about Epidermolysis Bullosa.

This year we are joining the DEBRA campaign INSIDE OUT, in benefit for the local patient organization DEBRA Sweden.

EB Awareness Week is an annual global initiative focused on increasing understanding of Epidermolysis Bullosa (EB), supporting affected individuals and families, and promoting research and advocacy.

https://www.debra-international.org/inside-out-2026

INSIDE OUT is an international campaign to raise awareness of EB and vital funds for those living with this painful, incurable condition. It means wearing your clothes inside out for a day to highlight the daily reality for children with EB, who often wear clothing this way to avoid painful seams against their fragile skin.

Join us for **INSIDE OUT** and show your support. Donate 50 SEK / 5 Euro or more to the EB patient organization DEBRA Sweden or your local DEBRA organization and mark the gift INSIDE OUT

/The Xinnate team

debra International. inside out

About Xinnate AB

Xinnate is a Swedish clinical-stage drug development company developing novel therapies based on its unique, groundbreaking peptide technology. These therapies address dysfunctional healing by modulating the interaction between microbes and inflammatory processes. With an ambitious development program, Xinnate is dedicated to improving the lives of, primarily, patients with Epidermolysis Bullosa. Xinnate is a member of the SmiLe Venture Hub at Medicon Village in Lund.

About TCP-25

TCP-25 is a novel immunomodulatory peptide with demonstrated anti-inflammatory, antimicrobial, and wound-healing properties. Xinnate's lead drug candidate, TCP-25 gel, is a topical formulation developed for the treatment of Epidermolysis Bullosa (EB).

About the STEP study

The STEP study, protocol number TCP25-002, is a double-blinded, randomized, placebo controlled study designed to evaluate the efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed dystrophic EB (DEB) or junctional EB (JEB). The study uses intra-individual randomization, meaning that a pair of matched index wounds are randomized to local treatment with either TCP-25 gel or placebo. Approximately 32 patients from 4 years of age will be included in the study. The study is conducted in France, Greece, Italy, Spain, Sweden, and the United States. For more information about the study, please see www.clinicaltrials.gov, ID: NCT06594393.